세계의 당뇨병성 신경병증 시장 보고서(2025년)

Diabetic neuropathy is a form of nerve damage that can affect individuals with diabetes, often resulting from elevated blood sugar levels that cause damage to blood vessels. This condition can impact various nerves in the body, including those in the feet, organs, and muscles.

The primary types of diabetic neuropathy include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Peripheral neuropathy occurs when the peripheral nerves, responsible for transmitting information between the brain, spinal cord, and the rest of the body, are damaged. Treatment for diabetic neuropathy involves various classes of drugs, such as analgesics, anti-depressants, anti-convulsant, and others, along with approaches such as drug treatment, radiotherapy, physiotherapy, and more. These treatments are made available through different distribution channels, including online and offline channels, and are utilized in settings such as hospitals, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The diabetic neuropathy market research report is one of a series of new reports from The Business Research Company that provides diabetic neuropathy market statistics, including diabetic neuropathy industry global market size, regional shares, competitors with a diabetic neuropathy market share, detailed diabetic neuropathy market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic neuropathy industry. This diabetic neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetic neuropathy market size has grown strongly in recent years. It will grow from $5.79 billion in 2024 to $6.21 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rising global diabetes prevalence, increased awareness and diagnosis, advancements in diabetic care, growing healthcare expenditure, research and development investments, patient education initiatives.

The diabetic neuropathy market size is expected to see rapid growth in the next few years. It will grow to $9.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to advancements in neuroimaging, patient-centric care approaches, expansion of clinical trials, continued rise in diabetes cases, precision medicine approaches, expansion of regenerative medicine, patient advocacy and support programs. Major trends in the forecast period include collaborative efforts in medical research, digital health solutions, advancements in diagnostic technologies, neuroprotective therapies, personalized treatment strategies, integration of artificial intelligence.

The forecast of 10.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. neurology care by inflating prices of pregabalin and duloxetine formulations imported from India and Israel, resulting in inadequate pain management and higher patient out-of-pocket costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The projected increase in diabetes prevalence is anticipated to drive substantial growth within the diabetic neuropathy market. Diabetes, a persistent condition characterized by the body's inability to adequately use and store glucose, leads to various forms of nerve damage known as diabetic neuropathy. As highlighted in the IDF Diabetes Atlas report released by the International Diabetes Federation in August 2022, the global toll from diabetes-related deaths amounted to 6.7 million in 2021, equating to one fatality every five seconds. Presently, there are approximately 537 million adults (aged 20-79) living with diabetes worldwide, a figure predicted to surge to 643 million by 2030 and 783 million by 2045. This escalating diabetes prevalence significantly contributes to the burgeoning diabetic neuropathy market.

The expanding proportion of the elderly population is poised to fuel the growth of the diabetic neuropathy market. As individuals age, the likelihood of developing diabetes and associated complications, including neuropathy, increases. Diabetic neuropathy encompasses nerve damage common in diabetic individuals, leading to symptoms such as numbness, tingling, and pain in affected areas. As per projections by the World Health Organization in October 2022, by 2030, one out of every six individuals globally will be aged 60 years or older, with the population of those aged 60 years and above set to surge from 1 billion in 2020 to 1.4 billion. By 2050, the worldwide population of individuals aged 60 years and older is expected to double, reaching 2.1 billion, with the number of individuals aged 80 years or older tripling to 426 million. This aging demographic is expected to drive demand for diabetic neuropathy treatments.

Major companies in the diabetic neuropathy market are developing advanced products, such as neuromodulation therapy devices, to improve treatment options for patients experiencing chronic pain linked to diabetic neuropathy. These devices provide non-invasive treatment by modulating nerve activity to alleviate pain, enhance nerve function, and promote healing in individuals with diabetic nerve damage. For example, in January 2024, Neuralace Medical, Inc., a US-based company specializing in non-drug pain management treatments, received approval from the Food and Drug Administration (FDA) for its Axon Therapy designed for Chronic Painful Diabetic Neuropathy (CPDN). This innovative device employs neuromodulation techniques to relieve pain associated with diabetic neuropathy, representing a significant advancement in pain management options for affected patients. The FDA clearance highlights the device's safety and efficacy, enabling Neuralace to proceed with commercialization and broaden access to effective treatment solutions for those suffering from CPDN.

Prominent companies within the diabetic neuropathy market are actively pursuing strategic partnerships and alliances to foster innovation and fortify their market positions. These alliances, formal agreements between multiple businesses, aim to leverage shared resources, knowledge, or expertise to achieve mutual objectives. For instance, in July 2022, Teva Pharmaceutical Industries Ltd., an Israel-based clinical-stage biopharmaceutical company, joined forces with NeuroFront Therapeutics Limited, a Hong Kong-based biotech firm, in an exclusive alliance and commercialization pact for Novaremed's pioneering non-opioid investigational drug, NRD.E1. This drug is specifically designed to treat diabetes-associated neuropathic pain and other related indications. This strategic collaboration enables the development and commercialization of an innovative therapy for neuropathic pain management.

In January 2022, Withings SA, a France-based consumer electronics company specializing in clinically validated smart health devices and associated apps, completed the acquisition of Impeto Medical SAS for an undisclosed sum. This strategic acquisition empowers Withings to integrate Impeto's cutting-edge technologies, including nerve tracking activity, into its product portfolio and services. Impeto Medical SAS, a France-based medical device company, manufactures tools for monitoring peripheral neuropathies to detect small fiber neuropathies in various diseases and conditions. This acquisition strengthens Withings' capabilities by incorporating advanced nerve tracking technologies, enhancing their offerings for neuropathy monitoring and management within their health devices and services lineup.

Major companies operating in the diabetic neuropathy market include Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Biogen Inc., Genentech Inc.

North America was the largest region in the diabetic neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in the diabetic neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the diabetic neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic neuropathy market consists of sales of drugs such as anticonvulsants, pain medications, nerve growth factor inhibitors and other drugs that are used to treat the symptoms of nerve damage caused by diabetes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Neuropathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic neuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic neuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetic neuropathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disorder: Peripheral Neuropathy; Autonomic Neuropathy; Proximal Neuropathy; Focal Neuropathy
• 2) By Drug Class: Analgesics; Anti-Depressants; Anti-Convulsants; Other Drug Classes
• 3) By Treatment: Drug Treatment; Radiotherapy; Physiotherapy; Other Treatments
• 4) By Distribution Channel: Online Distribution; Offline Distribution
• 5) By End-User: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Peripheral Neuropathy: Distal Symmetric Neuropathy; Mononeuropathy; Polyneuropathy
• 2) By Autonomic Neuropathy: Cardiovascular Autonomic Neuropathy; Gastrointestinal Autonomic Neuropathy; Genitourinary Autonomic Neuropathy
• 3) By Proximal Neuropathy: Diabetic Amyotrophy; Lumbosacral Plexus Neuropathy
• 4) By Focal Neuropathy: Cranial Neuropathy; Cervical Radiculopathy; Other Focal Neuropathies
• Companies Mentioned: Pfizer Inc.; Eli Lilly and Company; Daiichi Sankyo Company Limited; Johnson & Johnson; Depomed Inc.; F. Hoffmann-La Roche AG; NeuroMetrix Inc; Lupin Limited; Novartis AG; Boehringer Ingelheim; Regenacy Pharmaceuticals Inc.; Merck & Co. Inc.; Sanofi S.A.; Teva Pharmaceutical Industries Ltd.; AstraZeneca plc; Bayer AG; Bristol-Myers Squibb Company; Merck KGaA; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; Zydus Cadila; Biogen Inc.; Genentech Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Neuropathy Market Characteristics

3. Diabetic Neuropathy Market Trends And Strategies

4. Diabetic Neuropathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Diabetic Neuropathy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Neuropathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Neuropathy Market Growth Rate Analysis
• 5.4. Global Diabetic Neuropathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Neuropathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Neuropathy Total Addressable Market (TAM)

6. Diabetic Neuropathy Market Segmentation

• 6.1. Global Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy
• 6.2. Global Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesics
• Anti-Depressants
• Anti-consulvants
• Other Drug Classes
• 6.3. Global Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug Treatment
• Radiotherapy
• Physiotherapy
• Other Treatments
• 6.4. Global Diabetic Neuropathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Distribution
• Offline Distribution
• 6.5. Global Diabetic Neuropathy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-users
• 6.6. Global Diabetic Neuropathy Market, Sub-Segmentation Of Peripheral Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Distal Symmetric Neuropathy
• Mononeuropathy
• Polyneuropathy
• 6.7. Global Diabetic Neuropathy Market, Sub-Segmentation Of Autonomic Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular Autonomic Neuropathy
• Gastrointestinal Autonomic Neuropathy
• Genitourinary Autonomic Neuropathy
• 6.8. Global Diabetic Neuropathy Market, Sub-Segmentation Of Proximal Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diabetic Amyotrophy
• Lumbosacral Plexus Neuropathy
• 6.9. Global Diabetic Neuropathy Market, Sub-Segmentation Of Focal Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cranial Neuropathy
• Cervical Radiculopathy
• Other Focal Neuropathies

7. Diabetic Neuropathy Market Regional And Country Analysis

• 7.1. Global Diabetic Neuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Neuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Neuropathy Market

• 8.1. Asia-Pacific Diabetic Neuropathy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Neuropathy Market

• 9.1. China Diabetic Neuropathy Market Overview
• 9.2. China Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Neuropathy Market

• 10.1. India Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Neuropathy Market

• 11.1. Japan Diabetic Neuropathy Market Overview
• 11.2. Japan Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Neuropathy Market

• 12.1. Australia Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Neuropathy Market

• 13.1. Indonesia Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Neuropathy Market

• 14.1. South Korea Diabetic Neuropathy Market Overview
• 14.2. South Korea Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Neuropathy Market

• 15.1. Western Europe Diabetic Neuropathy Market Overview
• 15.2. Western Europe Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Neuropathy Market

• 16.1. UK Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Neuropathy Market

• 17.1. Germany Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Neuropathy Market

• 18.1. France Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Neuropathy Market

• 19.1. Italy Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Neuropathy Market

• 20.1. Spain Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Neuropathy Market

• 21.1. Eastern Europe Diabetic Neuropathy Market Overview
• 21.2. Eastern Europe Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Neuropathy Market

• 22.1. Russia Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Neuropathy Market

• 23.1. North America Diabetic Neuropathy Market Overview
• 23.2. North America Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Neuropathy Market

• 24.1. USA Diabetic Neuropathy Market Overview
• 24.2. USA Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Neuropathy Market

• 25.1. Canada Diabetic Neuropathy Market Overview
• 25.2. Canada Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Neuropathy Market

• 26.1. South America Diabetic Neuropathy Market Overview
• 26.2. South America Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Neuropathy Market

• 27.1. Brazil Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Neuropathy Market

• 28.1. Middle East Diabetic Neuropathy Market Overview
• 28.2. Middle East Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Neuropathy Market

• 29.1. Africa Diabetic Neuropathy Market Overview
• 29.2. Africa Diabetic Neuropathy Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Neuropathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Neuropathy Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Neuropathy Market Competitive Landscape
• 30.2. Diabetic Neuropathy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Depomed Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Neuropathy Market Other Major And Innovative Companies

• 31.1. F. Hoffmann-La Roche AG
• 31.2. NeuroMetrix Inc
• 31.3. Lupin Limited
• 31.4. Novartis AG
• 31.5. Boehringer Ingelheim
• 31.6. Regenacy Pharmaceuticals Inc.
• 31.7. Merck & Co. Inc.
• 31.8. Sanofi S.A.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. AstraZeneca plc
• 31.11. Bayer AG
• 31.12. Bristol-Myers Squibb Company
• 31.13. Merck KGaA
• 31.14. Novo Nordisk A/S
• 31.15. Takeda Pharmaceutical Company Limited

32. Global Diabetic Neuropathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Neuropathy Market

34. Recent Developments In The Diabetic Neuropathy Market

35. Diabetic Neuropathy Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Neuropathy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Neuropathy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Neuropathy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer